Bank of America
CADX

Bank of America’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Bank of America’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-26,669
Closed -$241K – 8564
2013
Q4 		$241K Buy
26,669
+1,338
+5% +$9.66K ﹤0.01% 5419
2013
Q3 		$160K Buy
25,331
+2,325
+10% +$14.8K ﹤0.01% 5640
2013
Q2 		$157K Buy
+23,006
New +$160K ﹤0.01% 5846

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Bank of America's CADX Position: Q1 2014 in Review

Bank of America sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 26,669 shares — an estimated $241K sold.

Bank of America first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $241K in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • Bank of America reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • Bank of America sold 26,669 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $241K.
  • Bank of America first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • Bank of America's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $241K in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Bank of America's 13F filing for Q1 2014, filed 15 May 2014.